

Regulation of cyclic GMP and cyclic AMP production by *S*-nitroso-cysteine in rat thymocytes

Mamiko Miyakoshi, Takehiro Yamada, Hiroyuki Katayama, Toshihiko Murayama *, Yasuyuki Nomura

Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo 060-0812, Japan

Received 28 May 1998; revised 17 August 1998; accepted 21 August 1998

Abstract

Nitrogen monoxides regulate cellular functions via cyclic GMP accumulation induced by nitric oxide (NO). However, the effects of NO on the cyclic AMP system have not been studied in detail. In this study, we investigated the effects of various NO donors on cyclic GMP and cyclic AMP accumulation in rat thymocytes. Addition of *S*-nitroso-cysteine stimulated cyclic GMP accumulation at concentrations up to 10 μ M, but was inhibitory at higher concentrations. Other NO donors such as sodium nitroprusside stimulated cyclic GMP accumulation markedly without causing inhibition. *S*-Nitroso-cysteine, but not other NO donors, inhibited forskolin-stimulated cyclic AMP accumulation in intact thymocytes and thymocyte membrane preparations. The inhibitory effect of *S*-nitroso-cysteine on cyclic AMP accumulation in membranes was partially reversed by dithiothreitol treatment. These findings suggest that the cyclic AMP system in thymocytes is specifically modified by *S*-nitroso-cysteine, and not by the NO/cyclic GMP system. © 1998 Elsevier Science B.V. All rights reserved.

Keywords: Nitrogen monoxide; *S*-Nitroso-cysteine; Cyclic nucleotide; Adenylyl cyclase; Thymocyte

1. Introduction

The thymus is a key organ of the immune system and is the primary site of T cell lymphopoiesis. The presence of α_2 -adrenoceptors (Marchetti et al., 1994) and adenosine receptors (Szondy, 1994) in the rat thymus has been reported, as well as cyclic AMP potentiated DNA fragmentation and thymocyte death (McConkey et al., 1993; Szondy, 1994). Additionally, the presence of muscarinic acetylcholine receptors, elevation of cyclic GMP levels, and regulation of functions by receptor stimulation have been reported (Maslinski et al., 1988). Previously, we reported on the presence of muscarinic M_3 receptors and carbachol-stimulated DNA fragmentation (Yamada et al., 1997), and showed that the addition of chemical nitric oxide (NO) donors such as sodium nitroprusside and dibutyl cyclic GMP inhibited DNA synthesis in rat thymocytes (Yamada et al., 1998). These reports suggest that cyclic AMP and cyclic GMP act as second messengers in thymocytes.

Nitrogen monoxides including NO are important cellular regulators in various systems including the nervous and immune systems. However, the broader chemistry of nitrogen monoxides involves various species such as NO, the nitrosonium cation (NO^+) and the nitroxyl anion (NO^-) (for review, see Stamler et al., 1992). One of the well-established effects of NO is the activation of guanylyl cyclase/cyclic GMP production. The functions of this pathway have been reviewed by Murad (1994). Although multiple nitric oxide synthase systems exist in the adult rat thymus (Downing, 1994), the levels of cyclic GMP in thymocytes have not been established. The effects of NO (and/or cyclic GMP) on the other second messenger, cyclic AMP, in thymocytes have also not been studied. In this study, we investigated the effects of chemical NO donors on cyclic GMP and cyclic AMP levels in rat thymocytes to examine the interactions between NO and cyclic AMP levels. All NO donors including *S*-nitroso-cysteine used in this study stimulated cyclic GMP accumulation via NO. High concentrations of *S*-nitroso-cysteine, but not of other NO donors, inhibited cyclic GMP and cyclic AMP in rat thymocytes. The inhibitory effect of *S*-nitroso-cysteine on adenylyl cyclase in the membranes was

* Corresponding author. Tel.: +81-11-706-3248; Fax: +81-11-706-4987.

relatively stable, but treatment with dithiothreitol, a reducing agent, blocked this inhibition. The physiological role of *S*-nitroso-cysteine as an intermediate of nitrogen monoxides is discussed.

2. Materials and methods

2.1. Animals and materials

Male Sprague–Dawley rats (5 weeks) were obtained from NRC Haruna (Gunma, Japan). They were provided with a commercial feed ad libitum for 1 week under specific pathogen-free conditions before use. All animal experiments were carried out in accordance with the NIH Guidelines for the Care and Use of Laboratory Animals and were approved by the animal care and use committee of Hokkaido University. Cyclic GMP and cyclic AMP assay kits were donated by the Yamasa-Shoyu (Chiba, Japan). *S*-Nitroso-*N*-acetylpenicillamine, sodium nitroprusside and NaNO₂ were obtained from Wako Pure Chemical (Osaka, Japan). *S*-Nitroso-cysteine and 1-hydroxy-2-*oxo*-3,3-bis(2-aminoethyl)-1-triazene (NOC-18) were gifts from Drs. Katayama and Miyazaki (Dojindo Lab., Kumamoto, Japan); *S*-nitroso-cysteine was synthesized as described by Lei et al. (1992) with modifications. Guanosine 5'-(3-*O*-thio)triphosphate (GTP γ S) was purchased from Boehringer-Mannheim (Germany).

2.2. Isolation of thymocytes

Rats were killed by decapitation and their thymuses were removed. We used decapitation instead of deep anesthesia in order to avoid the effects of anesthetics and the contamination of the thymocyte preparation with blood. Stem cell suspensions were obtained by teasing the tissue through a nylon mesh filter (300 \times 300 μ m) in modified Krebs–Ringer buffer (119 mM NaCl, 5 mM KCl, 1.2 mM CaCl₂, 1.2 mM KH₂PO₄, 1.2 mM MgSO₄, 15 mM glucose, 10 mM HEPES, pH 7.2), as described previously (Yamada et al., 1997, 1998). The cells were resuspended in ammonium chloride–Tris buffer (144 mM NH₄Cl, 17 mM Tris, pH 7.2) and incubated for 5 min at 4°C in order to hemolyse the erythrocytes and other cells. The cells were washed three times by centrifugation (300 \times *g*, 2 min, 4°C) and resuspended in buffer. The contamination of antigen-presenting cells such as dendritic cells and macrophages was less than 2%, as measured by morphological observation and by reactivity with anti-rat macrophage antibodies (Inter-cell Tec.). The purity of the thymocytes was higher than 95%.

2.3. Measurement of cyclic GMP and cyclic AMP content

The thymocytes ((2–4) \times 10⁵ cells/tube) were incubated with the indicated NO donors for 5 min at 37°C in

Krebs–Ringer buffer supplemented with 0.2 mM Ro-20-1724 (4-(3-butoxy-4-methoxybenzyl)-2-imidazolidione), 0.2 mM rolipram and 0.5 mM 3-isobutyl-1-methylxanthine as phosphodiesterase inhibitors. Incubations were terminated by acidification with HCl to 0.2 M and then boiling for 1 min. The cyclic GMP and cyclic AMP present in the supernatant were quantified by radioimmunoassay.

2.4. Measurement of adenylyl cyclase activity

The thymocytes were homogenized with 10 volumes of 20 mM Tris–HCl (pH 7.4), 1 mM EDTA, 0.5 mM phenylmethanesulfonyl fluoride, 0.5 mM benzamidine, and 4 μ g ml^{−1} of DNase using a glass-Teflon homogenizer. The homogenate was centrifuged at 300 \times *g* for 1 min, and the supernatant was further centrifuged at 40 000 \times *g* for 20 min at 4°C. The pellets were resuspended in 20 mM Tris–HCl (pH 7.4), 5 mM MgCl₂ and 0.2 mM EGTA, and washed twice with the same buffer. The assay for adenylyl cyclase activity was initiated by the addition of membrane suspensions to 200 μ l of 20 mM Tris–HCl (pH 7.4) containing 5 mM MgCl₂, 0.2 mM EGTA, 0.2 mM ATP, 5 mM phosphocreatine, 30 unit ml^{−1} of phosphocreatine kinase, three different phosphodiesterase inhibitors, and 0.1% bovine serum albumin. Further additions were as indicated in the legends of the figures and tables. After 20 min at 30°C, the reaction was stopped by acidification with HCl and boiling. Protein was determined using a BioRad assay kit with bovine serum albumin as the standard.

2.5. Statistical significances

Data were analyzed using the unpaired *t*-test. *P* values < 0.01 were considered to be significant.

3. Results

3.1. NO-dependent stimulatory effect and -independent inhibitory effect of *S*-nitroso-cysteine on cyclic GMP accumulation in rat thymocytes

Fig. 1 shows that the addition of *S*-nitroso-cysteine at concentrations up to 10 μ M remarkably stimulated cyclic GMP accumulation. However, *S*-nitroso-cysteine at concentrations over 10 μ M inhibited cyclic GMP accumulation. The ED₅₀ of *S*-nitroso-cysteine in the stimulatory phase was 3.6 \pm 2.2 μ M (*n* = 3), and the ED₅₀ in the inhibitory phase was 140 \pm 60 μ M (*n* = 3). Thus, *S*-nitroso-cysteine had a biphasic effect on cyclic GMP accumulation in rat thymocytes. The addition of sodium nitroprusside and *S*-nitroso-*N*-acetylpenicillamine stimulated cyclic GMP accumulation in a concentration-dependent manner, without an inhibitory phase (Fig. 2). NOC-18 also stimulated cyclic GMP accumulation in a concentration-dependent up to 500 μ M (see Table 1) without caus-




Fig. 1. Stimulatory and inhibitory effects of *S*-nitroso-cysteine on cyclic GMP accumulation in rat thymocytes. Rat thymocytes were incubated with the indicated concentrations of *S*-nitroso-cysteine in the presence (●) and absence (○) of 500 μ M *S*-nitroso-*N*-acetylpenicillamine. SNAP, *S*-nitroso-*N*-acetylpenicillamine. Data are means \pm S.E. of three independent experiments.

ing an inhibitory phase. The addition of 500 μ M NaNO_2 , but not NaNO_3 , stimulated cyclic GMP accumulation. The increase in cyclic GMP induced by NO donors including *S*-nitroso-cysteine seemed to be derived from the release of NO, because the addition of 1 mg/ml of oxyhemoglobin, which binds and inactivates NO (Rettori et al., 1993;




Fig. 2. Stimulatory effects of sodium nitroprusside and *S*-nitroso-*N*-acetylpenicillamine on cyclic GMP accumulation. Rat thymocytes were incubated with the indicated concentrations of sodium nitroprusside (○) and *S*-nitroso-*N*-acetylpenicillamine (●). SNP, sodium nitroprusside; SNAP, *S*-nitroso-*N*-acetylpenicillamine. Data are means \pm S.E. of three independent experiments.

Table 1

Inhibitory effect of oxyhemoglobin on NO donor-stimulated cyclic GMP accumulation in rat thymocytes

Addition	Cyclic GMP accumulation (pmol/10 ⁶ cells per 5 min)	
	None	Oxyhemoglobin (1 mg ml ⁻¹)
None	0.07 \pm 0.01	0.08 \pm 0.01
SNC (10 μ M)	10.9 \pm 1.5	0.13 \pm 0.02
SNP (500 μ M)	12.1 \pm 1.5	0.12 \pm 0.01
SNAP (500 μ M)	11.5 \pm 1.8	16.3 \pm 1.6
NOC-18 (500 μ M)	3.40 \pm 0.41	0.10 \pm 0.12
NaNO_2 (500 μ M)	3.05 \pm 0.22	Not determined

The thymocytes were incubated with the indicated NO donors in the presence or absence of 1 mg/ml of oxyhemoglobin. SNC, *S*-nitroso-cysteine. SNP, sodium nitroprusside. SNAP, *S*-nitroso-*N*-acetylpenicillamine. Data shown are means \pm S.D. of three determinations in a typical experiment and are representative of three independent experiments. The absolute values of three independent experiments agreed to within \pm 30%.

Lonart and Johnson, 1995; Satoh et al., 1996a,b), abolished the effects of *S*-nitroso-cysteine, sodium nitroprusside, and NOC-18 (Table 1). These findings show that the effect of *S*-nitroso-cysteine on cyclic GMP accumulation is exerted via NO. Penicillamine and *N*-acetylpenicillamine (400 μ M), the degradation products of *S*-nitroso-*N*-acetylpenicillamine, and cysteine (400 μ M) had no effect on cyclic GMP accumulation (data not shown). *S*-Nitrosoglutathione (400 μ M) did not stimulate cyclic GMP accumulation. *S*-Nitroso-*N*-acetylpenicillamine-stimulated increases in cyclic GMP were not inhibited by oxyhemoglobin.

The inhibitory effect of *S*-nitroso-cysteine at higher concentrations was observed in the presence of 500 μ M *S*-nitroso-*N*-acetylpenicillamine (Fig. 1). Under these conditions, *S*-nitroso-cysteine did not further enhance the *S*-nitroso-*N*-acetylpenicillamine-stimulated accumulation of cyclic GMP. The inhibitory effects of *S*-nitroso-cysteine at high concentrations in the presence of *S*-nitroso-*N*-acetylpenicillamine were observed in the presence of 1 mg/ml of oxyhemoglobin.

3.2. Inhibitory effect of *S*-nitroso-cysteine on cyclic AMP accumulation in rat thymocytes

Next, we investigated the effects of NO donors on cyclic AMP accumulation in rat thymocytes. The addition of 400 μ M *S*-nitroso-cysteine, but not sodium nitroprusside or *S*-nitroso-*N*-acetylpenicillamine, remarkably inhibited the basal (non-stimulated) cyclic AMP content (Table 2). Also *S*-nitroso-cysteine inhibited forskolin-stimulated cyclic AMP accumulation in intact thymocytes (Table 2 and Fig. 3). Forskolin-stimulated cyclic AMP accumulation was inhibited by the addition of *S*-nitroso-cysteine to the assay mixture in a concentration-dependent manner (Fig. 3). Significant inhibition was obtained with 100 μ M

Table 2
Effects of NO donors on cyclic AMP accumulation in rat thymocytes

Addition	Cyclic AMP accumulation (pmol/10 ⁶ cells per 5 min)	
	None	10 μ M Forskolin
None	2.1 \pm 0.2	21.1 \pm 1.3
400 μ M SNC	0.8 \pm 0.2	2.8 \pm 1.9
400 μ M SNP	2.4 \pm 0.1	21.4 \pm 1.3
400 μ M SNAP	2.5 \pm 0.1	24.9 \pm 1.6

The thymocytes were incubated with the indicated NO donors in the presence or absence of 10 μ M forskolin. SNC, *S*-nitroso-cysteine. SNP, sodium nitroprusside. SNAP, *S*-nitroso-*N*-acetylpenicillamine. Data shown are means \pm S.D. of three determinations in a typical experiment and are representative of three independent experiments. The absolute values of three independent experiments agreed to within \pm 30%.

S-nitroso-cysteine and the ED₅₀ values for inhibition, in the range of concentrations examined, was 250 \pm 30 μ M (n = 3).

It has been reported that NO donors increase cytosolic free Ca²⁺ concentrations in PC12 cells (Clementi et al., 1996). Some types of adenylyl cyclase are regulated by Ca²⁺ (for review, see Tang and Gilman, 1992) and a rise in cytosolic free Ca²⁺ concentrations induced by Ca²⁺ ionophores has been shown to inhibit cyclic AMP accumulation in 3T3 cells (Murayama and Ui, 1985). In our study with rat thymocytes, the addition of 10 μ M ionomycin inhibited 10 μ M-forskolin-stimulated cyclic AMP accumulation (5.1 \pm 1.0 and 21.1 \pm 1.3 pmol cyclic AMP/10⁶ cells per 5 min (n = 3) in the presence or absence of 10




Fig. 3. Inhibitory effect of *S*-nitroso-cysteine on cyclic AMP accumulation and adenylyl cyclase activity in rat thymocytes. Intact rat thymocytes (○) or thymocyte membranes (△) were incubated with the indicated concentrations of *S*-nitroso-cysteine in the presence of 10 μ M forskolin. Cyclic AMP accumulation and adenylyl cyclase activity were determined as described in Materials and Methods. Data are normalized as percentages of the forskolin-stimulated activity and are presented as means \pm S.E. of 3–4 independent experiments. The absolute values for forskolin-stimulated cyclic AMP accumulation and adenylyl cyclase activity were 24.3 \pm 3.8 pmol/10⁶ cells per 5 min (n = 4) and 11.3 \pm 1.3 pmol/mg protein per min (n = 3), respectively.

μ M ionomycin, respectively). However, basal and forskolin-stimulated cyclic AMP accumulation was not modified by the removal of extracellular CaCl₂ or by pretreatment for 10 min with 50 μ M BAPTA-AM, a cell-permeable chelator of Ca²⁺, in the absence of CaCl₂. These reactions were not modified by pretreatment with the calmodulin antagonist, 10 μ M W-7 (data not shown). Also the inhibitory effects of 500 μ M *S*-nitroso-cysteine on basal and forskolin-stimulated cyclic AMP accumulation were not modified by either treatment.

3.3. Inhibitory effect of *S*-nitroso-cysteine on adenylyl cyclase in the membranes and its reversal by dithiothreitol treatment

In membranes from rat thymocytes, *S*-nitroso-cysteine at 20 μ M inhibited 10 μ M forskolin-stimulated adenylyl cyclase activity significantly, with a maximal inhibition by *S*-nitroso-cysteine occurring at 200 μ M (Fig. 3). The ED₅₀ value of *S*-nitroso-cysteine for inhibition of membrane adenylyl cyclase activity was 55 \pm 15 μ M (n = 4), which was much higher than the ED₅₀ value for intact thymocytes. Adenylyl cyclase activity in the membranes was stimulated by both 10 μ M forskolin and 100 μ M GTP γ S (Table 3). In membranes first incubated with 0.4 mM *S*-nitroso-cysteine for 10 min and then washed with *S*-nitroso-cysteine-free buffer, the basal (non-stimulated), GTP γ S- and forskolin-stimulated adenylyl cyclase activity was significantly inhibited. Thus, the effect of *S*-nitroso-cysteine on adenylyl cyclase was not reversed by washing the membranes. Interestingly, the second incubation of the *S*-nitroso-cysteine-treated membranes with dithiothreitol caused significant, but not complete, restoration of GTP γ S- and forskolin-stimulated adenylyl cyclase activity. Treating the membranes with 5 mM dithiothreitol had no effect on

Table 3
Reversal of *S*-nitroso-cysteine-induced inhibition of adenylyl cyclase by treatment with dithiothreitol

	Adenylyl cyclase activity (%)			
1st treatment with SNC	–	–	+	+
2nd treatment with DTT	–	+	–	+
None	100	110 \pm 5	46 \pm 21	118 \pm 21
100 μ M GTP γ S	100	98 \pm 1	40 \pm 8	77 \pm 12 ^a
10 μ M Forskolin	100	99 \pm 1	43 \pm 12	77 \pm 10 ^a

The thymocyte membranes were first incubated with or without 0.4 mM *S*-nitroso-cysteine for 10 min at 30°C, and then the washed membranes were incubated with or without 5 mM dithiothreitol for 10 min at 30°C. After the membranes were washed, the adenylyl cyclase activity of the membranes was determined in the presence of 100 μ M GTP γ S, 10 μ M forskolin or vehicle. SNC, *S*-nitroso-cysteine; DTT, dithiothreitol. Data are normalized as percentages of the activity in the control membranes and are presented as means \pm S.E. of 3–4 independent experiments. The absolute values for control, GTP γ S- and forskolin-stimulated adenylyl cyclase activity in the control membranes (without treatments) were 2.55 \pm 0.29, 13.7 \pm 1.5 and 11.3 \pm 1.3 pmol/mg protein per min, respectively. Data were analyzed by the unpaired *t*-tests. ^a P < 0.01 vs. without secondary dithiothreitol treatment.

basal, GTP γ S- or forskolin-stimulated activity. Although the effect of dithiothreitol was not significant because of large variations, secondary treatment with dithiothreitol also restored the basal activity in *S*-nitroso-cysteine-treated membranes. The effect of another reducing agent, 2-mercaptoethanol (5 mM), was limited; treating the membranes with 5 mM 2-mercaptoethanol had no effect on basal, GTP γ S- or forskolin-stimulated adenylyl cyclase activity, and the second incubation of the *S*-nitroso-cysteine-treated membranes with 2-mercaptoethanol did not restore adenylyl cyclase activity (basal, 48 ± 11 ; GTP γ S-stimulated, 42 ± 9 ; forskolin-stimulated, $44 \pm 14\%$, which were almost the same as those without 2-mercaptoethanol).

4. Discussion

4.1. Cyclic GMP accumulation via NO in rat thymocytes

We reported earlier that addition of sodium nitroprusside or NaNO₂ to culture medium markedly inhibited concanavalin A-stimulated [³H]thymidine incorporation. Addition of 1 mM dibutyl cyclic GMP also inhibited concanavalin A-stimulated DNA synthesis significantly (Yamada et al., 1998). These findings suggest that the NO-cyclic GMP system regulates DNA synthesis in rat thymocytes. The addition of NO donors stimulated cyclic GMP accumulation in rat thymocytes. The effects of sodium nitroprusside, *S*-nitroso-*N*-acetylpenicillamine and *S*-nitroso-cysteine (up to 10 μ M) were concentration-dependent (Figs. 1 and 2). The effect of sodium nitroprusside and *S*-nitroso-cysteine seemed to be derived from the release of NO into the assay mixture, because (1) the effects of NO donors except *S*-nitroso-*N*-acetylpenicillamine were completely abolished by oxyhemoglobin (Table 1) and (2) addition of NOC-18, which releases NO selectively in acidic and neutral conditions (Hrabie et al., 1993), also stimulated cyclic GMP (Table 1).

S-Nitroso-*N*-acetylpenicillamine-stimulated cyclic GMP accumulation was not inhibited by oxyhemoglobin. Kowaluk and Fung (1990) previously reported that the release of NO from *S*-nitroso-*N*-acetylpenicillamine is not spontaneous and might be catalyzed by cell membranes. Our finding and this report together suggest that NO is produced by *S*-nitroso-*N*-acetylpenicillamine in intracellular compartments of thymocytes, as suggested for the hippocampus (Sato et al., 1996a,b). Because the effects of *S*-nitroso-*N*-acetylpenicillamine in other cell types have been shown to be inhibited by oxyhemoglobin, the effects of *S*-nitroso-*N*-acetylpenicillamine may be dependent on the cell type studied.

4.2. Inhibitory effects of *S*-nitroso-cysteine at higher concentrations on cyclic GMP and cyclic AMP accumulation

S-Nitroso-cysteine at concentrations over 10 μ M inhibited cyclic GMP (Fig. 1) and cyclic AMP accumulation

(Fig. 3 and Table 2). The inhibitory effects of *S*-nitroso-cysteine on cyclic nucleotides did not seem to be due to NO, because (1) other NO donors including NOC-18 did not inhibit either cyclic AMP or cyclic GMP and (2) high concentrations of *S*-nitroso-cysteine inhibited cyclic GMP in the presence of oxyhemoglobin (1 mg/ml). These findings also exclude the involvement of cyclic GMP in cyclic AMP inhibition and the inhibition of cyclic GMP accumulation by high concentrations of *S*-nitroso-cysteine, at least under our conditions. Addition of *S*-nitroso-cysteine to the assay mixture inhibited the adenylyl cyclase activity of the membranes (Fig. 3). Thus, it is probable that there is not substantial cross-talk between the cyclic GMP and cyclic AMP pathways in these cells, and that *S*-nitroso-cysteine inhibits both cyclic AMP and cyclic GMP accumulation directly.

Mayer et al. (1992) reported that cyclic GMP phosphodiesterase was activated and cyclic GMP formation was apparently inhibited by NO in brain synaptosomes. In our assay mixture, however, three kinds of phosphodiesterase inhibitors at sufficient concentrations were added. It has been suggested that sulfhydryl groups may be critical for the regulation of guanylyl cyclase, and that thiols regulate this activity by redox mechanisms (Niroomand et al., 1989; Murad, 1994; Mayer et al., 1995). Thus, it is likely that *S*-nitroso-cysteine, but not NO, directly interacts and inhibits guanylyl cyclase.

It has been reported that NO donors modulate cytosolic free Ca²⁺ concentrations in some cells (Shin et al., 1992; Mery et al., 1993; Clementi et al., 1996). Some types of adenylyl cyclase are known to be regulated by Ca²⁺/calmodulin (for review, see Tang and Gilman, 1992). However, Ca²⁺ was not involved in the *S*-nitroso-cysteine-induced inhibition of cyclic AMP accumulation, because removal of extracellular CaCl₂ and treatment with a calmodulin antagonist had no effect on *S*-nitroso-cysteine-induced inhibition. Adenylyl cyclase activity in thymocyte membranes in the absence of CaCl₂ was inhibited by the addition of *S*-nitroso-cysteine to the assay mixture (Fig. 3). These findings suggest that the inhibition of cyclic AMP accumulation by *S*-nitroso-cysteine is caused by the direct inhibition of adenylyl cyclase in the membranes.

4.3. Inhibition of adenylyl cyclase by *S*-nitroso-cysteine and its reversal by dithiothreitol treatment

Nitrogen monoxides such as NO interact directly with various protein molecules (for review, see Stamler, 1994) including adenylyl cyclase. Duhe et al. (1994) reported that critical cysteine residues of Ca²⁺/calmodulin-sensitive type I adenylyl cyclase are modulated by NO and *S*-nitroso-cysteine, thus inhibiting activity, and that dithiothreitol partially restored this activity. However, there are three major differences between our results and their results, namely, the target adenylyl cyclase in thymocytes is

not Ca^{2+} /calmodulin-sensitive, the inhibitory effect on adenylyl cyclase in thymocytes was obtained only with *S*-nitroso-cysteine, and NO is not involved in *S*-nitroso-cysteine-induced inhibition of this activity. The first discrepancy can be explained by the existence of Ca^{2+} /calmodulin-insensitive adenylyl cyclase in rat thymocytes. Because all reported adenylyl cyclases contain cysteine residues (Tang and Gilman, 1992), it is likely that Ca^{2+} /calmodulin-insensitive adenylyl cyclase(s) is the target for *S*-nitroso-cysteine in rat thymocytes. The types of adenylyl cyclase in rat thymocytes are now being investigated. The second and third discrepancies seem to depend on the experimental conditions or cell types used. It is probable that NO reacts with intracellular molecules containing cysteine and resultant molecules such as *S*-nitroso-cysteine exert an inhibiting effect in some cells, but the level of these molecules may be low in thymocytes. In agreement with the results by Duhe et al. (1994), however, the inhibition of adenylyl cyclase activity by *S*-nitroso-cysteine was reversed by treating the thymocyte membranes with dithiothreitol (Table 3).

There are several mechanisms which are regulated by nitrogen monoxides (for review, see Stamler, 1994). NAD-dependent modifications including NAD attachment are probable, as in the case of glyceraldehyde-3-phosphate dehydrogenase (Molina et al., 1992; McDonald and Moss, 1993), and studies have indicated that these modifications are stimulated by *S*-nitrosothiols and related nitrosating agents, rather than by NO itself (Mohr et al., 1994). However, the inhibition of adenylyl cyclase by *S*-nitroso-cysteine was observed in the membranes without NAD in our studies. *S*-Nitrosylation of protein thiols by NO donors is another important regulatory mechanism. Inactivation of glutathione peroxidase (Asahi et al., 1995) and protein kinase C (Gopalakrishna et al., 1993) by NO donors is partially reversed by the addition of dithiothreitol. Because the inhibitory effect of *S*-nitroso-cysteine on adenylyl cyclase was stable and not reversed by washing the membranes, and the addition of dithiothreitol restored the adenylyl cyclase activity in the *S*-nitroso-cysteine-treated membranes, *S*-nitrosylation of the cysteine residues of adenylyl cyclase by *S*-nitroso-cysteine is one of the most plausible mechanisms for its inhibitory activity. Alternatively, *S*-nitroso-cysteine may interfere with disulfide bonds in adenylyl cyclase or GTP-binding proteins. Further studies are needed to determine the mechanisms of action of *S*-nitroso-cysteine on adenylyl (and guanylyl) cyclases.

4.4. Physiological relevance of *S*-nitrosothiols and *S*-nitroso-cysteine

It is well known that, in the presence of metals, NO is easily converted into other active molecule. Our results show that *S*-nitroso-cysteine, but not cysteine or NO, is involved in the inhibition of adenylyl cyclase in rat thymo-

cytes. In a preliminary experiment, co-addition of 0.5 mM *S*-nitroso-*N*-acetylpenicillamine and 1 mM cysteine inhibited forskolin-stimulated cyclic AMP accumulation (data not shown). Previously, we reported that co-addition of NO donors (sodium nitroprusside and *S*-nitroso-*N*-acetylpenicillamine) with thiol agents (dithiothreitol and cysteine) stimulated noradrenaline release from rat hippocampus in vitro and in vivo in a NO/cyclic GMP-independent manner (Satoh et al., 1996a,b). Although NO donors such as sodium nitroprusside and *S*-nitroso-*N*-acetylpenicillamine by themselves had no effect, *S*-nitroso-cysteine stimulates noradrenaline release without co-factors (Satoh et al., 1997). Myers et al. (1990) reported that the vasorelaxant properties of the endothelium-derived relaxing factor more closely resembled those of *S*-nitroso-cysteine than those of NO. *S*-Nitrosothiol groups in proteins may serve as stable intermediates in the cellular metabolism of NO (Stamler, 1994). *S*-Nitrosothiols including *S*-nitroso-cysteine are formed under physiological conditions by several reaction mechanisms (Kharitonov et al., 1995; Gow et al., 1997). These results and previous reports suggest the formation and biological role of *S*-nitrosothiols under physiological conditions. We reported earlier that the effect of *S*-nitroso-cysteine on noradrenaline release in the hippocampus was inhibited markedly by specific amino acids such as L-leucine and L-alanine, and a specific inhibitor of the L-type amino acid transporter, 2-aminobicyclo[2.2.1]heptane-2-carboxylate, inhibited the effects of *S*-nitroso-cysteine (Satoh et al., 1997). The effect of *S*-nitroso-cysteine on cyclic GMP accumulation was not inhibited by L-leucine. These findings show that *S*-nitroso-cysteine was incorporated into rat hippocampus via L-type-like amino acid transporters and stimulated noradrenaline release. It is probable that *S*-nitroso-cysteine is incorporated and has direct effects on rat thymocytes, in addition to the generation of NO/cyclic GMP accumulation. The physiological significance of the inhibition of cyclic GMP accumulation and adenylyl cyclase activity by *S*-nitroso-cysteine in rat thymocytes remains to be determined.

Acknowledgements

This study was supported in part by Grants-in-Aid from the Ministry of Education, Science, Sports and Culture, Japan, and from the Research Foundation for Pharmaceutical Research in Japan.

References

- Asahi, M., Fujii, J., Suzuki, K., Seo, H.G., Kuzuya, T., Hori, M., Tada, M., Fujii, S., Taniguchi, N., 1995. Inactivation of glutathione peroxidase by nitric oxide. *J. Biol. Chem.* 270, 21035–21039.

- Clementi, E., Riccio, M., Sciorati, C., Nistico, G., Meldolesi, J., 1996. The type 2 ryanodine receptor of neurosecretory PC12 cells is activated by cyclic ADP-ribose. *J. Biol. Chem.* 271, 17739–17745.
- Downing, L.E.G., 1994. Multiple nitric oxide synthase systems in adult rat thymus revealed using NADPH diaphorase histochemistry. *Immunology* 82, 659–664.
- Duhe, R.J., Nielsen, M.D., Dittman, A.H., Villacres, E.C., Choi, E.-J., Storm, D.R., 1994. Oxidation of critical cysteine residues of type I adenylyl cyclase by *o*-iodosobenzoate or nitric oxide reversibly inhibits stimulation by calcium and calmodulin. *J. Biol. Chem.* 269, 7290–7296.
- Gopalakrishna, R., Chen, Z.H., Gundimeda, U., 1993. Nitric oxide and nitric oxide-generating agents induce a reversible inactivation of protein kinase C activity and phorbol ester binding. *J. Biol. Chem.* 268, 27180–27185.
- Gow, A.J., Buerk, D.G., Ischiropoulos, H., 1997. A novel reaction mechanism for the formation of *S*-nitrosothiol in vivo. *J. Biol. Chem.* 272, 2841–2845.
- Hrabie, J.A., Klose, J.R., Wink, D.A., Keefer, L.K., 1993. New nitric oxide-releasing zwitterions derived from polyamines. *J. Org. Chem.* 58, 1472–1476.
- Kharitonov, V.G., Sundquist, A.R., Sharma, V.S., 1995. Kinetics of nitrosation of thiols by nitric oxide in the presence of oxygene. *J. Biol. Chem.* 270, 28158–28164.
- Kowaluk, E.A., Fung, H.-L., 1990. Spontaneous liberation of nitric oxide cannot account for in vitro vascular relaxation by *S*-nitrosothiols. *J. Pharmacol. Exp. Ther.* 255, 1256–1264.
- Lei, S.Z., Pan, Z.-H., Aggarwal, S.K., Chen, H.-S.V., Hartman, J., Sucher, N.J., Lipton, S.A., 1992. Effect of nitric oxide production on the redox modulatory site of the NMDA receptor-channel complex. *Neuron* 8, 1087–1099.
- Lonart, G., Johnson, K.M., 1995. Characterization of nitric oxide generator-induced hippocampal [³H]norepinephrine release. *J. Pharmacol. Exp. Ther.* 275, 7–13.
- Marchetti, B., Morale, M.C., Paradis, P., Bouvier, M., 1994. Characterization, expression, and hormonal control of a thymic α_2 -adrenergic receptor. *Am. J. Physiol.* 267, E718–E731.
- Maslinski, W., Kullberg, M., Nordström, Ö, Bartfai, T., 1988. Muscarinic receptors and receptor-mediated actions on rat thymocytes. *J. Neuroimmunol.* 17, 265–274.
- Mayer, B., Klatt, P., Böhme, E., Schmidt, K., 1992. Regulation of neuronal nitric oxide and cyclic GMP formation by Ca^{2+} . *J. Neurochem.* 59, 2024–2029.
- Mayer, B., Schrammel, A., Klatt, P., Koesling, D., Schmidt, K., 1995. Peroxynitrite-induced accumulation of cyclic GMP in endothelial cells and stimulation of purified soluble guanylyl cyclase. *J. Biol. Chem.* 270, 17355–17360.
- McConkey, D.J., Orrenius, S., Okret, S., Jondal, M., 1993. Cyclic AMP potentiates glucocorticoid-induced endogenous endonuclease activation in thymocytes. *FASEB J.* 7, 580–585.
- McDonald, L.J., Moss, J., 1993. Stimulation by nitric oxide of an NAD linkage to glyceraldehyde-3-phosphate dehydrogenase. *Proc. Natl. Acad. Sci. USA* 90, 6238–6241.
- Mery, P.-F., Pavoine, C., Belhassen, L., Pecker, F., Fishmeister, R., 1993. Nitric oxide regulates cardiac Ca^{2+} current. *J. Biol. Chem.* 268, 26286–26295.
- Mohr, S., Stamler, J.S., Brüne, B., 1994. Mechanism of covalent modification of glyceraldehyde-3-phosphate dehydrogenase at its active site thiol by nitric oxide, peroxynitrite and related nitrosating agents. *FEBS Lett.* 348, 223–227.
- Molina, V.L., McDonald, B., Reep, B., Brüne, B., Di Silvio, M., Billiar, T.R., Lapetina, E.G., 1992. Nitric oxide-induced *S*-nitrosylation of glyceraldehyde-3-phosphate dehydrogenase inhibits enzymatic activity and increases endogenous ADP-ribosylation. *J. Biol. Chem.* 267, 24929–24932.
- Murad, F., 1994. Regulation of cytosolic guanylyl cyclase by nitric oxide: the NO-cyclic GMP signal transduction system. *Adv. Pharmacol.* 26, 19–33.
- Murayama, T., Ui, M., 1985. Receptor-mediated inhibition of adenylate cyclase and stimulation of arachidonic acid release in 3T3 fibroblasts. *J. Biol. Chem.* 260, 7226–7233.
- Myers, P.R., Minor, R.L. Jr., Guerra, R. Jr., Bates, J.N., Harrison, D.G., 1990. Vasorelaxant properties of the endothelium-derived relaxing factor more closely resemble *S*-nitrosocysteine than nitric oxide. *Nature* 345, 161–163.
- Niroomand, F., Rössle, R., Mülsch, A., Böhme, E., 1989. Under anaerobic conditions, soluble guanylate cyclase is specifically stimulated by glutathione. *Biochem. Biophys. Res. Commun.* 161, 75–80.
- Rettori, V., Belova, N., Dees, W.L., Nyberg, C.L., Gimeno, M., McCann, S.M., 1993. Role of nitric oxide in the control of luteinizing hormone-releasing hormone release in vivo and in vitro. *Proc. Natl. Acad. Sci. USA* 90, 10130–10134.
- Satoh, S., Murayama, T., Nomura, Y., 1996a. Sodium nitroprusside stimulates noradrenaline release from rat hippocampal slices in the presence of dithiothreitol. *Brain Res.* 733, 167–174.
- Satoh, S., Kimura, T., Toda, M., Miyazaki, H., Ono, S., Narita, H., Murayama, T., Nomura, Y., 1996b. NO donors stimulate noradrenaline release from rat hippocampus in a calmodulin-dependent manner in the presence of L-cysteine. *J. Cell. Physiol.* 169, 87–96.
- Satoh, S., Kimura, T., Toda, M., Maekawa, M., Ono, S., Narita, H., Miyazaki, H., Murayama, T., Nomura, Y., 1997. Involvement of L-type-like amino acid transporters in *S*-nitroso-cysteine-stimulated noradrenaline release in the rat hippocampus. *J. Neurochem.* 69, 2197–2205.
- Shin, W.-S., Sasaki, T., Kato, M., Hara, M., Seko, A., Yang, W.-D., Shimamoto, N., Sugimoto, T., Toyo-oka, T., 1992. Autocrine and paracrine effects of endothelium-derived relaxing factor on intracellular Ca^{2+} of endothelial cells and vascular smooth muscle cells. *J. Biol. Chem.* 267, 20377–20382.
- Stamler, J.S., 1994. Redox signalling: nitrosylation and related target interactions of nitric oxide. *Cell* 78, 931–936.
- Stamler, J.S., Singel, D.J., Loscalzo, J., 1992. Biochemistry of nitric oxide and its redox-activated forms. *Science* 258, 1898–1902.
- Szondy, Z., 1994. Adenosine stimulates DNA fragmentation in human thymocytes by Ca^{2+} -mediated mechanisms. *Biochem. J.* 304, 877–885.
- Tang, W.-J., Gilman, A.G., 1992. Adenylyl cyclases. *Cell* 70, 869–872.
- Yamada, T., Murayama, T., Nomura, Y., 1997. Muscarinic acetylcholine receptors on rat thymocytes: their possible involvement in DNA fragmentation. *Jpn. J. Pharmacol.* 73, 311–316.
- Yamada, T., Murayama, T., Nomura, Y., 1998. Enhancement of expression of inducible NO synthase and inhibition of DNA synthesis in rat thymocytes by in vivo hydrocortisone treatment. *J. Neuroimmunol.* 81, 14–19.